Cambridge, Mass.-based Tarix Orphan, a privately held biopharmaceutical company focused on the treatment of rare neuromuscular disorders and connective tissue diseases, has received the FDA’s Fast Track Designation for TXA127 (angiotensin 1-7) to reduce skeletal muscle damage and fibrosis and thereby improve muscle strength in Duchenne Muscular Dystrophy (DMD) patients.
OSU joins PCORnet for healthcare delivery
Regeneron, Mitsubishi Tanabe partner
Merck Millipore, celares collaborate
The Pulse on Technology by Ashley Tointon
Choosing to participate in a clinical trial is a big decision that should be weighed carefully. According to the Center for Information and Study on Clinical Research Participation (CISCRP), fewer than 4% of all U.S. physicians participate in clinical trials and only 7% of Americans say their doctors have ever suggested that they participate in a clinical study.